期刊
BONE
卷 70, 期 -, 页码 62-65出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bone.2014.07.026
关键词
Osteoporosis; Mesenchymal stem cells; Osteoblasts; Bone mass; Bone strength
资金
- NIH [R21AR057515, R01AR061366, R01AR43052, R01AR04884]
- California Institute of Regenerative Medicine [DR2A-05302]
- Endowment for Aging Research at U. C. Davis
Osteoporosis is a disease of excess skeletal fragility that results from estrogen loss and aging. Age related bone loss has been attributed to both elevated bone resorption and insufficient bone formation. We developed a hybrid compound, LLP2A-Ale in which LLP2A has high affinity for the alpha 4 beta 1 integrin on mesenchymal stem cells (MSCs) and alendronate has high affinity for bone. When LLP2A-Ale was injected into mice, the compound directed MSCs to both trabecular and cortical bone surfaces and increased bone mass and bone strength. Additional studies are underway to further characterize this hybrid compound, LLP2A-Ale, and how it can be utilized for the treatment of bone loss resulting from hormone deficiency, aging, and inflammation and to augment bone fracture healing. This article is part of a Special Issue entitled Stem Cells and Bone. (C) 2014 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据